The DOI matches its OpenAlex record; 18 of the 18 references it cites were found in a registry or an index.
Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study
Abstract
PURPOSE: To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia. PATIENTS AND METHODS: Four hundred sixty-nine assessable advanced cancer patients were randomized to (1) oral megestrol acetate 800 mg/d liquid suspension plus placebo, (2) oral dronabinol 2.5 mg twice a day plus placebo, or (3) both agents. Eligible patients acknowledged that loss of appetite or weight was a problem and reported the loss of 5 pounds or more during 2 months and/or a daily intake of less than 20 calories/kg of body weight. RESULTS: Groups were comparable at baseline in age, sex, tumor type, weight loss, and performance status. A greater percentage of megestrol acetate-treated patients reported appetite improvement and weight gain compared with dronabinol-treated patients: 75% versus 49% (P =.0001) for appetite and 11% versus 3% (P =.02) for > or = 10% baseline weight gain. Combination treatment resulted in no significant differences in appetite or weight compared with megestrol acetate alone. The Functional Assessment of Anorexia/Cachexia Therapy questionnaire, which emphasizes anorexia-related questions, demonstrated an improvement in quality of life (QOL) among megestrol acetate-treated and combination-treated patients. The single-item Uniscale, a global QOL instrument, found comparable scores. Toxicity was also comparable, with the exception of an increased incidence of impotence among men who received megestrol acetate. CONCLUSION: In the doses and schedules we studied, megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with dronabinol alone. Combination therapy did not appear to confer additional benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walsh, D., Donnelly, S., & Rybicki, L. (2000) · Supportive Care in Cancer · doi:10.1007/s005200050281 · Cited by 623
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., & Shepard, K. V. (1995) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)00117-4 · Cited by 504
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., Krook, J. E., Wilwerding, M. B., Rowland, K. M., Camoriano, J. K., Novotny, P. J., & Christensen, B. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3299 · Cited by 343
Self-citationControlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia
Loprinzi, C. L., Ellison, N. M., Schaid, D. J., Krook, J. E., Athmann, L. M., Dose, A. M., Mailliard, J. A., Johnson, P. S., Ebbert, L. P., & Geeraerts, L. H. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1127 · Cited by 318
Self-citationCHANG, A. E., SHILING, D. J., STILLMAN, R. C., GOLDBERG, N. H., SEIPP, C. A., BAROFSKY, I., SIMON, R. M., & ROSENBERG, S. A. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-6-819 · Cited by 259
Sloan, J. A., Loprinzi, C. L., Kuross, S. A., Miser, A. W., O'Fallon, J. R., Mahoney, M. R., Heid, I. M., Bretscher, M. E., & Vaught, N. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3662 · Cited by 241
Self-citationLoprinzi, C. L., Michalak, J. C., Schaid, D. J., Mailliard, J. A., Athmann, L. M., Goldberg, R. M., Tschetter, L. K., Hatfield, A. K., & Morton, R. F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.762 · Cited by 223
Self-citationA World Health Organizadon Demonstration Project, Nelson, K., Walsh, D., Deeter, P., & Sheehan, F. (1994) · Journal of Palliative Care · doi:10.1177/082585979401000105 · Cited by 215
Beal, J. E., Olson, R., Lefkowitz, L., Laubenstein, L., Bellman, P., Yangco, B., Morales, J. O., Murphy, R., Powderly, W., Plasse, T. F., et al. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(97)00038-9 · Cited by 206
FRYTAK, S., MOERTEL, C. G., O'FALLON, J. R., RUBIN, J., CREAGAN, E. T., O'CONNELL, M. J., SCHUTT, A. J., & SCHWARTAU, N. W. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-6-825 · Cited by 201
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
Cachexia: pathophysiology and clinical relevance1,2
Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.735 · Cited by 786
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Management of Cancer Cachexia: ASCO Guideline
Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00611 · Cited by 644
Self-citationCancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100092 · Cited by 586
Assessment and management of cancer-related fatigue in adults
Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14186-4 · Cited by 546
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Aizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., Etxebarria, N., & Usobiaga, A. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00949 · Cited by 467
Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review
Ali, S., & Garcia, J. M. (2014) · Gerontology · doi:10.1159/000356760 · Cited by 462
Cancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.-D., Schnelle, M., Reif, M., & Cerny, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1847 · Cited by 413
“Data from four dosefinding and phase II studies of 161 patients with cancer-related anorexia-cachexia syndrome (CACS) suggest cannabinoids’ potential at fixed doses of 2.5 mg of THC twice to three times daily;19-21 however, megestrol acetate palliated anorexia better than THC.22 We investigated the effects of CE and T…”
BackgroundInfluentialFatigue in palliative care patients — an EAPC approach
Radbruch, L., Strasser, F., Elsner, F., Gonçalves, J. F., Løge, J., Kaasa, S., Nauck, F., Stone, P., & the Research Steering Committee of the European Association for Palliative Care (EAPC) (2008) · Palliative Medicine · doi:10.1177/0269216307085183 · Cited by 317
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Abrams, D. I. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.003 · Cited by 296
Jatoi, A., Rowland, K., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., MacDonald, N., Gagnon, B., Novotny, P. J., Mailliard, J. A., Bushey, T. I. L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.024 · Cited by 296
Self-citationMegestrol acetate for treatment of anorexia-cachexia syndrome
Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., Gonzalvez Perales, J. L., & Bort-Martí, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004310.pub3 · Cited by 293
Cancer Cachexia: Mechanisms and Clinical Implications
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/601434 · Cited by 273
Brisbois, T. D., de Kock, I. H., Watanabe, S. M., Mirhosseini, M., Lamoureux, D. C., Chasen, M., MacDonald, N., Baracos, V. E., & Wismer, W. V. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq727 · Cited by 246
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Nutritional interventions for cancer-induced cachexia
Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2011.01.001 · Cited by 114
Symptom Management in Metastatic Breast Cancer
Irvin, W., Muss, H. B., & Mayer, D. K. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0159 · Cited by 112
Johnson, S., Ziegler, J., & August, D. A. (2021) · Nutrition in Clinical Practice · doi:10.1002/ncp.10639 · Cited by 14
Metadata
- Authors
- Jatoi, A., Windschitl, H. E., Loprinzi, C. L., Sloan, J. A., Dakhil, S. R., Mailliard, J. A., Pundaleeka, S., Kardinal, C. G., Fitch, T. R., Krook, J. E., Novotny, P. J., & Christensen, B.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-01-15
- Volume
- 20
- Issue
- 2
- Pages
- 567-573
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2159814416
- Cited by
- 543
- References
- 18
- FWCI
- 13.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.